Supplementary file 1_Evaluation of genetic variation in tumor suppressor miRNA encoding an

A 19.9 KB supplementary document from a 2026 study by Yogita Chhichholiya. It details findings from sequencing miRNA encoding regions and 3'UTRs of target genes in 208 breast cancer patients. The study includes results from functional analyses like luciferase assays and survival analyses using tools like Kaplan-Meier Plotter.

Use Cases

• Validate the impact of KRAS 3'UTR variants rs712 and rs9266 on miRNA binding based on luciferase assay results.
• Correlate hsa-let-7c and hsa-miR-181c expression levels with patient survival outcomes based on Kaplan-Meier analysis.
• Assess KRAS expression as a predictive biomarker for chemotherapy response based on ROC analysis.
• Study the structural impact of genetic variants on miRNA-target interactions based on RNAfold predictions.

Strengths

• Data is derived from sequencing 208 breast cancer patient samples, providing a specific cohort size.
• Includes results from multiple functional validation methods: luciferase assay, RT-PCR, IHC, and Western blotting.
• Analysis integrates clinical outcome data from tools like TNM plot and Kaplan-Meier Plotter.

Limitations

• The primary data file is a 19.9 KB DOCX document, which likely contains summary text and figures rather than raw, machine-readable data tables.
• Row count and column-level documentation for any underlying data are unknown, limiting suitability assessment.
• Description metadata is limited; actual data quality and structure require manual inspection after download.

Provenance

Source

figshare, author Yogita Chhichholiya.

Collection Method

Sequencing of miRNA encoding regions and 3'UTRs of target genes (KRAS, IGFBP6, IGF1R) in patient samples, followed by functional assays.

Freshness

Last updated 2026-03-18 07:39:40.